Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | completed | Phase 1 | 21 | Brian JonasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02686593 |
| Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML |
| completed |
| Phase 2 |
| 50 |
| The University of Hong KongOTHER |
| 1 |
| Oct 6, 2022 |
| clinicaltrials |
| NCT04177576 | Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms(MPN-BIOCLOT) | completed | — | 397 | University Hospital, BordeauxOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT00053157 | Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia | completed | N/A | 10 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05563207 | Application of Health Education Path of Traditional Chinese Medicine Nursin | completed | N/A | 60 | Shijiazhuang Pingan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02065154 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | completed | Phase 2 | 39 | University of Alabama at BirminghamOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT05541224 | A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers | completed | — | 6,917 | PETHEMA FoundationOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | completed | Phase 1 | 39 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05488717 | The Effect of Art-Based Mandala on Mental Health in Bone Marrow Transplant Patients | completed | N/A | 46 | Aysenur UcerizOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01682226 | Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies | completed | Phase 2 | 84 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01168219 | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01253070 | Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03723681 | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04452604 | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19(COVLA) | completed | — | 79 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03035422 | Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia(SET-HAPLO) | completed | N/A | 24 | Association for Training, Education, and Research in Hematology, Immunology, and TransplantationOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03434704 | Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole(SIR-POSA) | completed | Phase 2 | 10 | Ciceri FabioOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01005277 | Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | completed | — | 2,000 | Children's Oncology GroupNETWORK | 1 | Jul 14, 2022 | clinicaltrials |
| NCT02758223 | Prophylactic Application of Donor-derived TCM After Allogeneic HSCT(PACT) | completed | Phase 1 / Phase 2 | 16 | Wuerzburg University HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05456048 | Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML | completed | — | 231 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05169307 | CPX-351 Real-World Effectiveness and Safety Study | completed | — | 147 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT00900055 | Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma | completed | — | 213 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT02109744 | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients(AML) | completed | Phase 1 / Phase 2 | 27 | University of RochesterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05421104 | Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | completed | — | 1,576 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01093573 | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 34 | Brenda Cooper, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01244750 | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting(SIMPLICITY) | completed | — | 1,494 | Bristol-Myers SquibbINDUSTRY | 8 | Jun 30, 2022 | clinicaltrials |
| NCT02551718 | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | completed | N/A | 34 | University of WashingtonOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03848754 | Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 14 | Medical College of WisconsinOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03509896 | Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | completed | — | 463 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(SEAMLESS) | completed | Phase 3 | 482 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 12 | Jun 22, 2022 | clinicaltrials |
| NCT04744974 | Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm | completed | Phase 2 | 28 | University of California, IrvineOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT04089839 | A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting | completed | — | 177 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03144687 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | completed | Phase 2 | 23 | Incyte CorporationINDUSTRY | 3 | Jun 16, 2022 | clinicaltrials |
| NCT02921802 | A Study of Special Use Results Surveillance of Revlimid 5mg Capsules | completed | — | 4,626 | CelgeneINDUSTRY | 1 | Jun 14, 2022 | clinicaltrials |
| NCT01667133 | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 35 | Ariad PharmaceuticalsINDUSTRY | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02842320 | Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)(CAR-LMC) | completed | N/A | 53 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04788420 | Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML | completed | — | 456 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03483324 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | completed | Phase 1 | 10 | Angiocrine BioscienceINDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT05387330 | Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment | completed | — | 35 | Tanta UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03128411 | Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | May 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2022source: clinicaltrials